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Abstract
Background—Stress-induced hypertrophic remodeling is a critical pathogenetic process leading
to heart failure. While many signal transduction cascades are demonstrated as important regulators
to facilitate the induction of cardiac hypertrophy, the signaling pathways for suppressing
hypertrophic remodeling remain largely unexplored. In this study, we identified p21-activated
kinase 1 (Pak1) as a novel signaling regulator which antagonizes cardiac hypertrophy.
Methods and Results—Hypertrophic stress applied to primary neonatal rat cardiomyocytes
(NRCMs), or murine hearts caused the activation of Pak1. Analysis of NRCMs expressing
constitutively active Pak1 or in which Pak1 was silenced disclosed that Pak1 played an anti-
hypertrophic role. To investigate the in vivo role of Pak1 in the heart, we generated mice with a
cardiomyocyte-specific deletion of Pak1 (Pak1cko). When subject to 2 weeks of pressure overload,
Pak1cko mice compared to controls, developed greater cardiac hypertrophy with attendant blunting
of JNK activation, and these knockout mice underwent the transition into heart failure when
prolonged stress was applied. In addition, chronic angiotensin II infusion also caused increased
cardiac hypertrophy in Pak1cko mice. Moreover, we discovered that the Pak1 activator FTY720, a
sphingosine-like analogue, was able to prevent pressure overload-induced hypertrophy in wild-
type mice, without compromising their cardiac functions. Meanwhile FTY720 failed to exert such
Correspondence to: Dr. Xin Wang: Faculty of Life Sciences, the University of Manchester, CTF Building, Grafton Street, Manchester
M13 9NT, UK. Tel: +44 161 275 5616; Fax: +44 161 275 5600; xin.wang@manchester.ac.uk.
*Joint seniors
Conflict of Interest Disclosures None.
Subject codes: 15, 115, 130, 138
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing
this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it
is published in its final citable form. Please note that during the production process errors may be discovered which could affect the
content, and all legal disclaimers that apply to the journal pertain.
Europe PMC Funders Group
Author Manuscript
Circulation. Author manuscript; available in PMC 2012 June 13.
Published in final edited form as:
Circulation. 2011 December 13; 124(24): 2702–2715. doi:10.1161/CIRCULATIONAHA.111.048785.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
an effect on Pak1cko mice, suggesting that the anti-hypertrophic effect of FTY720 likely acts
through Pak1 activation.
Conclusions—These results, for the first time, establish Pak1 as a novel anti-hypertrophic
regulator and suggest that it may be a potential therapeutic target for the treatment of cardiac
hypertrophy and heart failure.
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Cardiac hypertrophy; heart failure; signal transduction; stress
Introduction
Cardiac hypertrophy is a critical pathogenetic process leading to heart failure, with an
incidence and prevalence that is rapidly increasing worldwide. The life time risk of heart
failure is one in five amongst both men and women. Cardiac hypertrophy is characterized as
proliferation-independent cardiomyocyte growth, which bears some similarity to tumour
growth. To date, many oncogenes have been demonstrated to positively regulate cardiac
hypertrophy. For example, aberrant activation of Ras (small guanine nucleotide-binding
protein) is a step in the development of many types of cancers 1. Cardiac overexpression of
constitutively active Ras manifested ventricular hypertrophy2. This evidence indicates that
the signaling programs regulating cell proliferation may be closely related to the programs
that control growth of postmitotic adult cardiomyocytes.
One of these signaling programs, which may be critical in both aberrant growth in cancer
and in cardiac hypertrophy, is a cascade involving p21-activated kinase 1 (Pak1), for which
there is provocative evidence for a role in tumour formation3, 4, yet the role of Pak1 in
cardiac hypertrophy signaling remains largely unexplored. The Pak family is a group of
evolutionarily conserved serine/threonine protein kinases consisting of six isoforms,
subdivided into two groups. Pak1 belongs to the group I subfamily, and was first discovered
as a major binding partner for small GTPases Rac1 and Cdc425. When cells face inciting
stimuli, Cdc42/Rac1 becomes activated via exchange of GDP for GTP6, and activated
Cdc42/Rac1 binds to Pak1, which in turn induces the activation of Pak17. At the last count,
approximately 40 proteins in various cell types have been identified as downstream effectors
of Pak1 reflecting the range of its biological activities, including regulation of cell
proliferation, cell survival and cell motility8. Pak1 is abundant in the heart. Important
findings by us and others lay the groundwork for suggesting the significant physiological
roles of this kinase in the heart9-12. In the present study, we aimed to examine our
hypothesis that Pak1 may play an important role in cardiac hypertrophy, and in the transition
to heart failure, and to investigate whether Pak1 is a potential therapeutic target for anti-
hypertrophic treatment.
Using both primary cardiomyocytes and Pak1cko mice, we discovered that Pak1 acts as a
novel signaling hub relaying anti-hypertrophic and survival signals from small GTPases to
the JNK cascade in the heart. Furthermore, we observed that application of FTY720, a
sphingosine-like synthetic analogue with an ability to activate Pak113, 14, prevented the
development of cardiac hypertrophy in load stressed wild-type mice, and its anti-
hypertrophic effect was likely due to its function to activate Pak1. Overall, these data
demonstrate for the first time that Pak1 activation exerts a beneficial effect by resisting
stress-induced hypertrophic remodeling, and Pak1 may thus be a potential therapeutic target
for anti-hypertrophic treatment.
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Methods
More detailed methods are available in the online Data Supplement.
Adenoviral Infection of NRCMs
Adenovirus-mediated gene transfection of NRCMs was performed by methods described
previously15. Adenovirus expressing shPak1 (CTGTTCTGGATGTGTTGGAAT) was
generated using the BLOCK-iT adenoviral RNAi expression system (Invitrogen).
Adenoviruses expressing caPak1 (constitutively active Pak1), or NFAT-luciferase reporter
gene (Ad-NFAT-Luc) were described elsewhere10, 16. Ad-caMKK7 (constitutively active
MKK7) was a kind gift from Dr. Hiroki Aoki (Kurume University, Japan). After infection,
NRCMs were subjected to immunocytochemistry, quantitative RT-PCR, immunoblot
analyses and luciferase reporter assay to investigate the role of Pak1 in cardiac hypertrophy.
Generation of Pak1f/f and Pak1cko Mice
Pak1 genomic DNA was used for constructing a gene targeting vector with two LoxP sites
flanking exon 3 of pak1. 129Sv-derived R1 embryonic stem (ES) cell transfection, selection,
screening and blastocyst injection were performed as described previously17. Germline
transmitting chimeras were generated and mated with C57BL/6 females to produce
heterozygous Pak1 flox mice, which were back-crossed into a C57BL/6 background for 5
generations to obtain homozygous Pak1 flox (Pak1f/f) mice. To generate Pak1cko mice,
Pak1f/f mice were mated with mice expressing Cre under α myosin heavy chain (αMHC)
promoter (αMHC-Cre)18. Quantitative RT-PCR, immunoblotting and immunostaining were
used to verify Pak1 deletion. All mice used in this study were maintained in a pathogen-free
facility at the University of Manchester. The animal studies were performed in accordance
with the UK Home Office and institutional guidelines.
Hypertrophy Models and FTY720 Administration
Cardiac hypertrophy was induced by administration of angiotensin II (Ang II, Sigma-
Aldrich) at 1μg/g/day for 14 days via osmotic mini-pumps (Alzet) implanted
subcutaneously in 8-10 week old male Pak1cko mice and their littermates (Pak1f/f mice), or
by transverse aortic constriction (TAC) as previously described15, 16, 19. For FTY720 (2-
amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol hydrochloride) administration, on the
second day after the operation, TAC- or sham-operated wild-type mice or Pak1cko mice
(C57BL/6 background, 8-10 week old male) were randomized into different groups for
intra-peritoneal injection of FTY720 (10μg/g/day, Cayman Chemical) or vehicle (saline) for
5 days. FTY720-LD50 [50% lethal dose] is 300 μg/g. 7 days after the operation (5 days post
FTY720 injection), hearts were taken from different experimental groups and the
hypertrophic responses were analyzed by histology, quantitative RT-PCR, echocardiography
and hemodynamic analysis.
Data Analysis
Two-way ANOVA followed by Bonferonni corrected post-hoc t-test was used for
comparisons among multiple groups. Comparisons between two groups were performed
using Student’s t-test. P-values <0.05 are considered statistically significant. Data are
expressed as mean ± SEM. Where sample sizes were < 5, tests were also conducted using
ranked data. In all cases statistical conclusion were the same. For simplicity we present only
the parametric results.
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Results
Pak1 Regulates the JNK Pathway and Antagonizes NFAT-Mediated Hypertrophy in NRCMs
In order to investigate the biological role of Pak1 in cardiac hypertrophy, we first
determined activation of endogenous Pak1 by various hypertrophic agonists. Stimulation of
NRCMs for 30 min with angiotensin II (Ang II, 10 μM), phenylephrine (PE, 30 μM), or
isoproterenol (ISO, 10 μM) each significantly increased Pak1 phosphorylation of Thr-423 in
the T-loop of Pak1, which is indicative of Pak1 activation (Figure 1A). Pak1
phosphorylation was also appreciably increased in ventricular tissues of wild type mice
subjected to transverse aortic constriction (TAC) for 2 weeks (Figure 1A). We next assessed
whether Pak1 exerts a pro-hypertrophic or an anti-hypertrophic effect in response to
hypertrophic stimuli in NRCMs. NRCMs were infected with the Ad-caPak1 (constitutively
active Pak1) or control adenovirus Ad-GFP prior to 48 h PE treatment. Unexpectedly, Ad-
caPak1 abrogated the pro-hypertrophic effect of PE, showing a significantly smaller cell
surface area concomitant with a nearly 2-fold down-regulation of ANP mRNA expression
(Figure 1B-C). Furthermore, we examined whether activated Pak1 affects NFAT
transcriptional activity, which plays a central role in regulating cardiac hypertrophy. In line
with results reported above, adenoviral infection of the NFAT-luciferase reporter (Ad-
NFAT-Luc) in control NRCMs (infected with Ad-LacZ) led to enhanced NFAT reporter
activity following PE stimulation. However, infection of Ad-caPak1 did not lead to any
increase in NFAT activity despite PE stimulation (Figure 1D). To corroborate these data, we
adopted a gene knockdown system in NRCMs, where Pak1 expression was deleted by 85%
following infection with Ad-shPak1; expression of Pak2 and Pak3 (close Pak family
isoforms) remained unchanged (Figure 2A). Compared to NRCMs infected with scrambled
shRNA (Ad-shC2), PE induced significantly greater increases in cell size and in ANP
mRNA level in NRCMs infected with Ad-shPak1 (Figure 2B-C).
To investigate the potential mechanism whereby Pak1 deficiency promoted hypertrophy, we
screened a range of hypertrophic regulators. Our data demonstrate a prominent defect in
JNK phosphorylation in shPak1-infected NRCMs after PE stimulation (Figure 2D).
Furthermore, MKK4 and MKK7 (upstream activators of JNK) were found not to respond to
PE stimulation in the absence of Pak1 (Figure 2D). However, phosphorylation levels of
MEKK1, p38, ERK1/2 and PKB were similar in the two groups following PE treatment
(Figure 2D).
Finally, NFAT transcriptional activity was examined when Pak1 was knocked down. We
discovered that PE stimulation of shPak1-infected NRCMs resulted in enhanced NFAT
activity. However, this increase in NFAT activity was mitigated by infection with
constitutively active MKK7 (Ad-caMKK7), indicating that loss of Pak1 induces greater
cardiomyocyte hypertrophy by promoting increased NFAT activity, which is likely to occur
via the JNK pathway (Figure 2E).
Generation and Characterization of Cardiomyocyte-Specific Pak1 Knockout Mice
Prompted by our results showing that Pak1 might be a critical signaling nexus limiting
hypertrophy, we moved on to studies addressing our hypothesis in the intact heart. To
precisely ascertain the in vivo role of Pak1 in the heart, we generated cardiomyocyte-
specific Pak1 deletion mice (Pak1cko). Mice with a germ-line modification in the pak1 gene
with two LoxP elements flanking exon 3 (Pak1f/f) were generated (Supplement Figure I A-
B). Pak1f/f mice were healthy and fertile, indicating that the presence of two LoxP sites did
not affect Pak1 function in vivo.
To establish Pak1cko mice, Pak1f/f mice were bred with αMHC-Cre mice. Pak1cko mice
developed to term, and were viable and fertile in adulthood. PCR amplification of genomic
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DNA prepared from cardiomyocytes, brain, liver and skeletal muscle of 8-week old Pak1f/f
and Pak1cko mice confirmed the specific recombination of the pak1 gene in cardiomyocytes
(Supplement Figure II A). The deletion of pak1 gene product in cardiomyocytes was
verified at mRNA and protein levels (Supplement Figure II B-D). Notably, loss of Pak1 in
cardiomyocytes did not induce any compensatory changes in the protein levels of its
activators, Cdc42 and Rac1, as well as its close family members Pak2 and Pak3, and
potential effectors, such as ERK1/2, JNK and p38 (Supplement Figure II D-E).
Disruption of Pak1 in Cardiomyocytes Exacerbates Pressure Overload-Induced
Hypertrophy
Following on, we determined whether Pak1 is involved in regulating cardiac hypertrophy.
Pressure overload by TAC was applied to 8-week old Pak1f/f and Pak1cko mice. Following 2
weeks of TAC, Pak1f/f mice developed a moderate 19% increase in heart weight/tibia length
(HW/TL) ratio, whereas Pak1cko mice showed a 53% increase in HW/TL ratio (Figure 3A).
Consistent with this result there was a significant increase in cross-sectional area of Pak1cko-
TAC cardiomyocytes (338.7±2.74 μm2), compared to 242.43±4.54 μm2 of Pak1f/f-TAC
cardiomyocytes (Figure 3B).
Sirius Red staining to determine collagen deposition (Figure 3C) showed more interstitial
fibrosis in Pak1cko-TAC myocardium (6.1% fibrotic area compared to 1.6% in the controls).
Loss of Pak1 also induced cardiomyocyte apoptosis indicated by a 5-fold increase in the
number of TUNEL-positive nuclei in Pak1cko-TAC myocardium compared to Pak1f/f hearts
(Figure 3D). Reactivation of the fetal gene program was measured by quantitative RT-PCR;
expression of ANP, brain natriuretic peptide (BNP) and β myosin heavy polypeptide (Myh7)
mRNA was significantly elevated in the hypertrophied Pak1cko myocardium (Figure 3E).
Regulator of calcineurin 1 variant 4 (RCAN1.4) is a target gene of NFAT transcription
factors. Increased RCAN1.4 mRNA expression was detected in TAC stressed Pak1cko
hearts, indicating enhanced NFAT signaling in the knockout mice (Figure 3E). Moreover, as
illustrated in Figure 3E, mRNA levels of procollagen type I, α2 (Col1α2) and procollagen
type III, α1 (Col3α1) were markedly up-regulated in the Pak1cko myocardium.
Although greater hypertrophy and salient remodeling occurred in the Pak1cko-TAC mice,
their contractile performance remained normal, as indicated by similar fractional shortening
(FS %) between the two groups after TAC (Supplement Table I). Thus we conclude that
ablation of Pak1 in cardiomyocytes promotes hypertrophic remodeling in response to TAC
stress.
Prolonged Load Stress Sensitizes Pak1cko Mice to Heart Failure
To further determine whether loss of Pak1 in cardiomyocytes predisposes mice to heart
failure, we extended the TAC stress imposed on Pak1f/f and Pak1cko mice to 5 weeks.
Indeed, Pak1cko mice showed characteristics of heart failure after TAC. Lung weight to tibia
length (LW/TL) ratio was substantially higher in Pak1cko-TAC mice, indicating pulmonary
edema due to contractile insufficiency (Figure 4A). A significant reduction in FS
(19.89±1.8%) in the knockouts confirmed heart failure, whereas Pak1f/f mice exhibited
preserved contractility (Figure 4B). The increases in HW/TL ratio (83%) and in myocyte
cross-sectional area (419.83±2.0 μm2) became even more prominent in Pak1cko mice after
prolonged TAC stress (Figure 4C-D). In addition, increased collagen deposition (9.1%) was
scattered over the working myocardium of Pak1cko-TAC mice (Figure 4E). These results
demonstrated that mice were more vulnerable to longer pressure overload stress, and more
readily made the transition into heart failure when Pak1 was absent.
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Enhanced Hypertrophic Remodeling is Induced in Pak1cko Mice Responding to Ang II
Infusion
To determine the general significance of our findings, we investigated whether Pak1 resists
hypertrophy induced by neuroendocrine stimuli. When subjected to 2-week infusion of Ang
II (1μg/g/day), Pak1cko mice demonstrated significantly increased hypertrophy, as reflected
by a 35% enhancement in HW/TL and enlarged cardiomyocytes (292.61±3.51μm2 versus
190.69±2.96μm2 of Pak1f/f myocytes) (Supplement Figure III A-B). Ventricular fibrosis
was more visible in the knockouts (Supplement Figure III C). We measured ROS production
by DHE staining; there were no significant differences detected between the two genotypes
(Supplement Figure III D). Also, cardiac function in Pak1cko mice was comparable to the
control group (Supplement Figure III E). Together, these results illustrate that Pak1
antagonizes cardiac hypertrophy not only by mechanical stress-induced membrane receptor
activation, but also by neuroendocrine agonist stimulation.
The JNK Cascade acts Downstream of Pak1 in Cardiac Hypertrophic Remodeling
To obtain in vivo evidence of the regulatory mechanism whereby Pak1 modulates
hypertrophic responses, we surveyed downstream candidates. Consistent with data that we
obtained from NRCMs, TAC treatment did not induce the activation of MKK4/MKK7-JNK
pathway in the Pak1cko myocardium, whereas activation of p38, ERK1/2 and PKB, as well
as PP2A activity (phosphorylation of Y307) remained the same between the two groups
(Figure 5A).
We also examined apoptotic molecules that might be responsible for the higher rate of
cardiomyocyte death in the knockout hearts. Interestingly, we found augmented protein
levels of p53, Bax and Bad in the Pak1cko-TAC myocardium. However, there were no
significant differences observed in either the expression of Bim and Bcl-2, or
phosphorylation of Bad at Ser 112 (Figure 5B), which is a known site for Pak1-mediated
phosphorylation20. Thus, these data demonstrate that the MKK4/MKK7-JNK pathway acts
downstream of Pak1 in protecting the heart from hypertrophic stress.
FTY720 Induces Pak1 Activation and Prevents Cardiac Hypertrophy
Led by the results above, we tested whether Pak1 is a potential therapeutic target for anti-
hypertrophic treatment. Firstly, we demonstrated FTY720 was able to induce Pak1
phosphorylation in NRCMs and in wild-type mouse myocardium (Figure 6A). Then, we
discovered that treatment of NRCMs with FTY720 (200nM, 48h) significantly reduced PE-
induced hypertrophic responses, indicated by a significantly smaller cell surface area
together with markedly decreased ANP expression (Figure 6B). Interestingly, Pak1-
knockdown NRCMs treated with or without FTY720 showed no significant differences in
PE-induced increases in cell surface area and ANP expression (Figure 6B), suggesting
FTY720 likely functions via Pak1 activation to block hypertrophic responses. Noteworthy,
using trypan blue staining to check cell viability, we found that FTY720 at a dose of 200nM
was sufficient to restrain hypertrophic responses, but did not exhibit a toxic effect on
NRCMs (Figure 6C), indicating FTY720 may be a suitable agent for anti-hypertrophic
therapy in vivo.
To test this hypothesis, we applied FTY720 (10μg/g/day of body weight) to wild-type mice
for 5 days commencing on the second day after TAC or sham operation. Treatment with
vehicle (saline) was given to the control groups following the same protocol. Notably, after
5 days of treatment with FTY720, TAC-mice showed comparable HW/TL ratio (6.01±0.22
mg/mm) and cardiomyocyte cross-sectional areas (196.73±3.06 μm2) to the FTY720-treated
sham-mice (HW/TL: 5.61±0.14 mg/mm; cross-sectional areas: 192.63±3.65 μm2) or
vehicle-treated sham-mice (HW/TL: 5.6±0.11 mg/mm; cross-sectional areas: 193.75±2.35
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μm2) (Figure 7A-B). Accordingly, echocardiography also demonstrated cardiac structure
and function of the FTY720-treated TAC-mice were similar to the sham groups (Figure 7C-
D). In contrast to the FTY720-treated TAC-mice, the TAC-mice treated with vehicle
developed hypertrophy (Figure 7A-D). Consistent with in vitro data, FTY720 used in this
protocol did not exhibit cardiac toxicity in the mice, as FS, dP/dtmax (contractile response)
and dP/dtmin (lusitropic response) in the FTY720 treated groups remained normal, compared
to the vehicle treated groups (Figure 7 E-F).
Next, we determined whether the anti-hypertrophic effect of FTY720 was due to Pak1
activation, therefore, the same FTY720 treatment protocol was applied to Pak1cko mice
subjected to either TAC or sham operation. Interestingly, despite FTY720 treatment, TAC
was still able to induce hypertrophy in the hearts of Pak1cko mice (HW/TL: 7.92±0.22 mg/
mm [FTY720] versus 8.06±0.2 mg/mm [vehicle]; cross-sectional areas: 310.76±3.02 μm2
[FTY720] versus 313.8±1.72 μm2 [vehicle]) (Figure 8A-B). Echocardiography and
hemodynamic analysis demonstrated comparable cardiac structure and function between the
FTY720 treated TAC-mice and the sham groups (Figure 8C-F).
Together, these data suggest that the activation of Pak1 by FTY720 is able to prevent the
development of cardiac hypertrophy.
Discussion
With the use of cultured rat cardiomyocytes and Pak1cko mice, we have identified a novel
cardioprotective role of Pak1 in attenuating cardiac hypertrophy and halting the transition to
heart failure. The major findings of this study are: 1) Pak1 is activated by both mechanical
stress and neuroendocrine agonists in the heart; 2) Pak1 is an indispensable upstream
activator for the JNK pathway in response to hypertrophic challenges; 3) Pak1 plays a
critical role in antagonising cardiac hypertrophy, since hearts of Pak1cko mice are vulnerable
to cardiac hypertrophy and readily progress to failure with application of sustained pressure
overload; 4) the activation of Pak1 by FTY720 is able to prevent the development of cardiac
hypertrophy, suggesting Pak1 may be a potentially important therapeutic target for anti-
hypertrophic treatment.
Pak1 is an Anti-Hypertrophic Regulator in the Heart
This study, for the first time, demonstrates a differing role for Pak1 in cardiomyocyte
growth. During the past decade, growing evidence has suggested that Pak1 activation is
frequently associated with cell proliferation, survival of cancer cells and increased
invasiveness. In fact, more than half of human breast cancers exhibit hyperactivation and/or
overexpression of Pak121. In cancers, Pak1 activation is inextricably linked with aberrant
Ras/Raf/ERK signaling8. In the heart, mature cardiomyocytes are terminally differentiated;
growth signals do not lead to proliferation but rather to hypertrophy, which explains why
many oncogenes display pro-hypertrophic effects in the adult heart22, 23. Thus, we predicted
that Pak1 may exert a similar function to that of the Ras pathway in facilitating cardiac
hypertrophy. However, to our surprise, our studies revealed the anti-hypertrophic property
of Pak1 in the heart.
The initiation of cardiac hypertrophy involves neuroendocrine factors, such as angiotensin
II, endothelin-1 and phenylephrine, all of which act on G-protein-coupled receptors
(GPCRs), in turn; these receptors stimulate heterotrimeric G-proteins such as Gq/11, G12/13,
and Gi for signal transduction24-26. However, small GTPases do not bind with GPCRs, but
become activated through exchange of GDP for GTP. The dynamic GTP-binding and GDP-
hydrolysis cycle of small GTPases is tightly regulated by GTPase activating proteins
(GAPs) and guanine nucleotide exchange factors (GEFs), which are downstream effectors of
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heterotrimeric G-proteins6, 27. Pressure overload is a potent hypertrophic inducer in the
heart. It not only induces the release of neuroendocrine factors to stimulate GPCRs, but also
activates stretch sensors or receptor tyrosine kinases for the development of cardiac
hypertrophy28. When the heart is exposed to various hypertrophic stimuli, pro-hypertrophic
and anti-hypertrophic signaling pathways are concurrently activated to regulate the
hypertrophic process. We discovered that Pak1 was activated by a number of
neuroendocrine factors, and by pressure overload to antagonize cardiac hypertrophy.
The Cdc42-Pak1-JNK Axis is a Critical Pathway Relaying Anti-Hypertrophic Signals
Results of studies investigating the role of Cdc42, a key regulator of Pak1 activation, in
hypertrophic signaling are consistent with our findings. Maillet et al. reported that diverse
hypertrophic stimuli increased the activated GTP-bound form of Cdc42. Loss of Cdc42 in
cardiomyocytes rendered mice more capable of cardiac hypertrophic growth, and Cdc42 is
required for JNK activation in response to hypertrophic stress29. Their data agree with
previous investigations in mammalian cells showing that Cdc42 induces JNK
activation30-32. Interestingly, Maillet et al. also showed that Cdc42 deficiency in NRCMs
led to blunted phosphorylation of MEKK1. MEKK1 is a MAP3K; which preferentially
activates the JNK pathway through MKK4 and MKK7, and also regulates the activity of the
ERK cascade33, 34. However, we did not observe altered MEKK1 phosphorylation due to
Pak1 deficiency; whereas blunted activation of the MKK4/MKK7-JNK pathway and
increased NFAT activity was detected when Pak1 was scarce. MKK4 and MKK7 are
upstream kinases for JNKs, which are implicated in the progression of heart failure35, 36.
JNKs have been shown to antagonize cardiac hypertrophy through inhibition of NFAT
activity37. Our recent studies employing mice with cardiomyocyte-specific deletion of
MKK4 or MKK7 support this mechanism16, 19. Considering the above evidence, we believe
that Pak1 acts upstream of the JNK pathway in hypertrophic signaling, and MEKK1 might
not be a direct effector downstream of Pak1-mediated anti-hypertrophic signaling.
It is interesting to note that a recent study by Higuchi et al. described a novel property of
Pak1; it not only has catalytic function, but can also act as a scaffolding protein for priming
Akt activation38. Whether Pak1 is able to directly phosphorylate MKK4/MKK7 or aid
recruitment of MKK4/MKK7 to specific MAP3Ks in response to hypertrophic stimuli thus
remains to be determined.
Our previous study has shown that Pak1 is involved in modulating cardiac contractility
through PP2A-mediated dephosphorylation of cardiac troponin I (cTnI)10. It was proposed
that p38 seemed to be an intermediate for Pak1-mediated PP2A activity10. As such, we have
examined p38 activation and PP2A phosphorylation of Y307 (indicating the catalytic
activity of PP2A), however, no alteration in p38 activation or PP2A activity was observed in
our experimental setting due to Pak1 deficiency in cardiomyocytes under TAC stress. These
results suggest at least in the model we have employed, that PP2A or p38 is unlikely to be
downstream of Pak1 and responsible for the development of cardiac hypertrophy.
Current knowledge of Cdc42 and Rac1, both of which activate Pak1, suggests differing roles
for these small G proteins in hypertrophic signaling in the heart. In contrast to the promotion
of cardiac hypertrophy by down-regulation of Cdc4229, down-regulation of Rac1 inhibits the
development of cardiac hypertrophy in response to Ang II infusion via decreased activity of
NADPH39. Subsequent studies by Custodis et al. indicated that Rac1 binding to Rho
guanine dissociation inhibitor α may be a mechanism by which Rac1 mediates hypertrophy
in a mouse pressure overload model40. Rac1 overexpression in myocardium induced
hypertrophy in juvenile transgenic mice concurrent with altered intracellular distribution of
Pak from the cytosol to cytoskeletal fraction41. Yet in this study by Sussman et al. no
information was provided as to which isoform of Pak was involved in the translocation41. It
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is known that other Pak isoforms, such as Pak2 and Pak3, which share substantial sequence
homology with Pak142, are also expressed in cardiomyocytes. We have demonstrated that
Pak1cko mice exhibited greater hypertrophy with no increase in ROS production after 2
weeks of Ang II infusion, which is in stark contrast to phenotypes reported in Rac1
cardiomyocyte-specific knockouts39. Taking this evidence into account it is plausible that
Pak1 is a primary effector of Cdc42 rather than Rac1. Pak1 is an indispensible component of
the Cdc42-Pak1-JNK axis serving as a critical anti-hypertrophic regulatory pathway.
Pak1 Activation by FTY720 Exerts a Beneficial Effect for Restraining Cardiac Hypertrophy
FTY720 is a sphingosine-like analogue, approved by the FDA for treating relapsing multiple
sclerosis. We have previously reported that FTY720 prevents arrhythmias in an ex vivo rat
heart subjected to ischemia/reperfusion injury14. In the ischemia/reperfusion model, Pak1
activation was suggested to be involved in an FTY720-induced protective effect14. Our test
to determine whether FTY720 activation of Pak1 extended to the induction of cardiac
hypertrophy demonstrated that administration of a pharmacological dose of FTY720 (10μg/
g/day) was sufficient and effective to limit TAC-induced cardiac hypertrophy in wild-type
mice. Meanwhile, the observation that FTY720 failed to block increased cardiac
hypertrophy in TAC stressed-Pak1cko mice provides further support that FTY720 induces its
anti-hypertrophic effect through the activation of Pak1.
Cardiac hypertrophy is traditionally regarded as an adaptive response to normalize
ventricular wall stress. According to Laplace’s law, FTY720 treatment might cause
deterioration in cardiac function and chamber dilation in TAC stressed mice due to limited
cardiac hypertrophy; however, none of these were observed in our study. Similarly, in
response to pressure overload, preserved cardiac function with no or little hypertrophy was
reported by a number of investigations, including studies in which NFAT signaling was
inhibited43-47. These findings suggest that hypertrophy may not always be a necessary
compensatory response; increased wall stress per se does not cause cardiac dysfunction.
Therefore, FTY720 treatment could be of clinical interest given the fact of its ability to
prevent hypertrophy, without deteriorating cardiac function. Furthermore, FTY720, which is
derived from myriocin48, a component of the natural product Isaria sinclairii, represents a
non-toxic sphingosine-like derivative with oral bioavailability that may be useful in
treatment and/or prevention of cardiac disorders in high-risk patients.
In conclusion, we have discovered a novel role for Pak1 as a critical signaling hub in
cardioprotection which limits excessive hypertrophic remodeling. Pak1 most likely acts
downstream of Cdc42 to convey both anti-hypertrophic and survival signals to the JNK
pathway in cardiomyocytes. Our demonstration of prevention of cardiac hypertrophy by
administration of FTY720 provides convincing evidence for the identification of Pak1 as a
potential therapeutic target for anti-hypertrophic treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CLINICAL PERSPECTIVE
Heart failure (HF) is one of the most devastating diseases. The life time risk of heart
failure is one in five amongst both men and women. Despite advances in diagnostic and
therapeutic technology during past decades, the survival rate after the onset of HF still
remains significantly high. There is general agreement that cardiac hypertrophy is a
determinant of the clinical course of HF. Therefore, understanding molecular
mechanisms of hypertrophic remodeling is a key step in deciphering the pathogenesis of
HF. Cardiac hypertrophy is characterized as proliferation-independent cardiomyocyte
growth. The signaling programs regulating cell proliferation may be closely related to the
programs that control growth of postmitotic adult cardiomyocytes. Based on this premise,
we identified p21-activated kinase 1 (Pak1), which is important in cell proliferation, as a
novel regulator antagonising cardiac hypertrophy. We have also elucidated that Pak1 is
an indispensible component of the anti-hypertrophic signaling, in which Cdc42 (small
GTPases) is its upstream activator, and JNK (MAP kinase) works downstream of Pak1.
Most interestingly, we discovered that FTY720 (a sphingosine-like analogue), a FDA
approved drug for treating relapsing multiple sclerosis, is able to limit cardiac
hypertrophy of murine hearts. This anti-hypertrophic effect of FTY720 is likely to
function through the activation of Pak1. Overall, our findings provide the evidence to
establish Pak1 as a novel anti-hypertrophic regulator and a potential therapeutic target for
the treatment of cardiac hypertrophy and heart failure.
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Figure 1.
Activated Pak1 attenuated hypertrophic responses in NRCMs. (A) Immunoblotting analyses
of Pak1 phosphorylation at Thr 423 indicate that Pak1 activation was induced by angiotensin
II (Ang II), phenylephrine (PE), and isoproterenol (ISO) in NRCMs (n=3), and by TAC
stress in myocardium (n=5 mice per group) (Western blot images: upper panel; the ratios of
P/T Pak1 are represented by the bar graphs: lower panel, *P=0.001 versus untreated
NRCMs). (B) Representative images of α-actinin immunostaining of NRCMs infected with
Ad-caPak1 or Ad-GFP (scale bar: 20μm). Quantification of cell surface area is presented in
the bar graph (n=3 independent experiments, 50 cells counted per experiment). (C) qPCR
analyses show decreased ANP mRNA expression in Ad-caPak1-infected NRCMs after PE
stimulation. The data are derived from 5 independent experiments performed in triplicate
and are normalized to the GAPDH content (n=5). (D) The luciferase reporter assays showed
increased NFAT transcriptional activity in control NRCMs (infected with Ad-LacZ) after PE
stimulation, whilst activated Pak1 (Ad-caPak1) diminished this increased NFAT
transcriptional activity. Data are means ± SEM, n=3 independent experiments.
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Figure 2.
Knockdown of Pak1 in NRCMs augmented hypertrophic responses. (A) NRCMs were
infected with Ad-shC2 or Ad-shPak1 for 72 hours prior to immunoblot analysis of Pak1
protein level. Pak2 and Pak3 protein levels were determined to examine the specificity of
Pak1 knockdown. GAPDH expression is the protein loading control. (B) Representative
images of α-actinin immunostaining of NRCMs infected with Ad-shC2 or Ad-shPak1 (scale
bar: 20μm). Quantification of cell surface area is presented in the bar graph (n=3
independent experiments, 50 cells counted per experiment). (C) qPCR analyses of ANP
mRNA expression (n=5). (D) Immunoblot analyses of expression and phosphorylation
levels of JNK, MKK4, MKK7, MEKK1, p38, ERK1/2 and PKB in response to PE for 30
minutes. (E) The luciferase reporter assays showed substantially increased NFAT
transcriptional activity in Ad-shPak1-infected NRCMs after PE stimulation, and activated
MKK7 repressed Pak1 deficiency-induced higher NFAT transcriptional activity. Data are
means ± SEM, n=4 independent experiments.
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Figure 3.
Exacerbated cardiac hypertrophy in Pak1cko mice after 2 weeks of TAC. (A) HW/TL ratios
of Pak1f/f and Pak1cko mice. (B) Measurements of mean cross-sectional area. (C)
Histological view of cardiac fibrosis detected by Sirius Red staining (scale bar: 50μm).
Quantification of the relative area of fibrosis is expressed as percentage fibrosis. (D)
Increased apoptosis in Pak1cko ventricular myocardium was detected by TUNEL assay.
TUNEL-positive nuclei are represented in the bar graph (n=5-7 mice per group). (E) qPCR
analyses of ANP, BNP, Myh7, RCAN1.4, Col1α2 and Col3α1. The data are normalized to
the GAPDH content (n=5-7 mice per group).
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Figure 4.
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Pak1cko mice exhibit signs of heart failure when exposed to prolonged TAC. (A) 5 weeks of
TAC caused a significant increase in lung weight relative to tibia length in Pak1cko mice.
(B) M-mode echocardiography show dilated ventricular chamber (left panel), and reduced
FS% (right panel) in Pak1cko-TAC mice. (C) HW/TL ratios of Pak1f/f and Pak1cko mice
(upper panel). Morphometry demonstrates greater hypertrophy in Pak1cko-TAC mice (lower
panel, scale bar: 2mm). (D) Measurements of mean cross-sectional areas (upper panel), and
hematoxylin & eosin staining of heart cross-sections (lower panel, scale bar: 20μm). (E)
Massive interstitial fibrosis in the Pak1cko heart (scale bar: 50μm). Quantification of fibrotic
area is presented in the bar graph (n=7 mice per group).
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Figure 5.
Pak1 is an upstream activator for the JNK pathway in response to TAC stress. (A) Protein
extracts from Pak1f/f and Pak1cko hearts were examined by immunoblotting for total JNK,
MKK4, MKK7, p38, ERK1/2, PKB and PP2A expression, as well as their phosphorylation
levels. The ratios of P/T JNK, P/T MKK4, P/T MKK7 and P/T PP2A are represented by the
bar graphs. (B) Immunoblot analyses of protein levels of p53, Bax, Bad, Bim and Bcl-2, as
well as phosphorylated Bad. GAPDH expression is the protein loading control. The ratios of
p53/GAPDH, Bax/Bcl-2 and Bad/Bcl-2 are represented by the bar graphs (n=6 mice per
group).
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Figure 6.
FTY720 induced Pak1 activation and prevented hypertrophic responses in NRCMs. (A)
FTY720-induced Pak1 phosphorylation was examined by immunoblot analyses in NRCMs
(100 nM, 1h), and in myocardium (10μg/g, 1h). Western blot images: upper panel; the ratios
of P/T Pak1 are represented by the bar graphs: lower panel; n=5. (B) Representative images
of triple staining of NRCMs (red staining for ANP, pointed by arrows; green for α-actinin;
blue for DAPI, scale bar: 20μm). Quantification of ANP-expressing cells or cell size is
presented by the bar graphs (n=5). (C) Trypan blue staining to detect cell viability after
FTY720 treatment in NRCMs infected with Ad-shPak1 or Ad-shC2 (scale bar: 100μm, n=4
independent experiments, 250 cells counted per experiment). .
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Figure 7.
FTY720 treatment prevented the induction of cardiac hypertrophy in the wild type TAC-
hearts, demonstrated by significant decreases in (A) HW/TL ratio, and in (B) mean cross-
sectional areas, compared to vehicle-treated TAC-hearts. Echocardiography showed (C)
increased ventricular posterior wall thickness (dPW) and (D) interventricular septal wall
thickness (dIVS) in vehicle-treated TAC-mice, but not in FTY720-treated TAC-mice. (E) FS
% and (F) In vivo hemodynamic analysis (dP/dtmax - contractile response and dP/dtmin -
lusitropic response) demonstrated that cardiac functions were preserved in FTY720-treated
groups (n=5-8 mice per group). * P=0.02, # P=0.01 versus vehicle-treated sham-mice,
respectively.
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Figure 8.
FTY720 failed to block increased cardiac hypertrophy in Pak1cko-TAC mice. (A) HW/TL
ratio, and (B) mean cross-sectional areas, showed no difference between vehicle- and
FTY720-treated Pak1cko-TAC mice, although TAC induced increased hypertrophy in both
groups, compared to sham-groups. Echocardiographic parameters of (C) dPW and (D) dIVS
are comparable between vehicle- and FTY720-treated Pak1cko-TAC mice. (E) FS% and (F)
dP/dtmax and dP/dtmin, show normal cardiac functions in FTY720-treated Pak1cko-TAC
mice (n=4-6 mice per group). * P= 0.03, # P=0.04 versus vehicle-treated sham-mice,
respectively.
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